Feb 4, 2025 Avalo Therapeutics to Present at Oppenheimer’s 35th Annual Healthcare Life Sciences Conference
Nov 12, 2024 Avalo Therapeutics Receives $69.4 Million in Proceeds from the Full Exercise of Private Placement Warrants
Oct 8, 2024 Avalo Announces First Patient Dosed in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa
